GLP1R and Parkinson disease: In this context, GLP-1R agonists have been shown to affect the central nervous system and exhibit neuroprotective properties in animal models of several neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, stroke, diabetic retinopathy, and ocular hypertension (McClean et al., 2011; Hao et al., 2012; Fan et al., 2014; Gonçalves et al., 2016; Zhang et al., 2018, 2019; Basalay et al., 2019; Yang et al., 2019; Chang et al., 2020; Ramos et al., 2020; Ren et al., 2020; Sterling et al., 2020; Zhai et al., 2020).